loading...| Preferred Name |
Nintedanib |
|
| Synonyms |
|
|
| Definitions |
An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C62765 |
|
| ALT_DEFINITION |
A substance being studied in the treatment of some types of cancer. BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. |
|
| CAS_Registry |
656247-17-5 |
|
| Chemical_Formula |
C31H33N5O4 |
|
| code |
C62765 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis. |
|
| Display_Name |
Nintedanib |
|
| FDA_UNII_Code |
G6HRD2P839 |
|
| Has_Salt_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Nintedanib |
|
| Legacy Concept Name |
BIBF_1120 |
|
| Maps_To |
Nintedanib |
|
| NCI_Drug_Dictionary_ID |
504524 |
|
| PDQ_Closed_Trial_Search_ID |
504524 |
|
| PDQ_Open_Trial_Search_ID |
504524 |
|
| Preferred_Name |
Nintedanib |
|
| prefixIRI |
NCIT:C62765 |
|
| prefLabel |
Nintedanib |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2930789 |
|
| subClassOf |